A severe COVID-19 despite ongoing treatment with Lopinavir-RitonavirComment Published on 2020-11-012023-07-11 Journal: Respiratory medicine and research [Category] SARS, [키워드] COVID-19 Human immunodeficiency virus Lopinavir Pneumonia Pulmonary embolism [DOI] 10.1016/j.resmer.2020.100780 PMC 바로가기 [Article Type] Comment
In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2Research article Published on 2020-11-012022-10-05 Journal: European journal of pharmacology [Category] SARS, 신약개발, [키워드] ACE2 addition angiotensin-converting enzyme 2 anti-inflammatory action antiviral drug approach approved drug bind binding binding energy can be used clinically COVID 19 COVID-19 docking drug Drug repurposing ENhance eriodictyol fatality globe HCQ Helicase Host Infection Interaction isoniazid Lopinavir molecular docking molecular docking analysis molecular interaction mycophenolic acid NSP pandemic Pemirolast Protein receptor Receptor binding domain researcher responsible SARS protein SARS-CoV-2 SARS-CoV-2 protein selected small molecule spike Spread supported target protein tested therapeutic treat Treatment understanding viral propagation virus was done [DOI] 10.1016/j.ejphar.2020.173430 [Article Type] Research article
SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidenceSARS-CoV-2 약리학적 치료법 및 근거 수준에 따른 안전성/유효성Review Published on 2020-11-012022-08-31 Journal: The American journal of emergency medicine [Category] meta-analysis, 임상, 치료제, [키워드] Antiviral article Chloroquine Cochrane Library COVID-19 COVID-19 clinical outcomes COVID-19 pharmacologic treatments COVID-19 transmission criteria Dexamethasone drug Drug effectiveness Drug safety effective Effectiveness English evaluate Evidence HCQ Hydroxychloroquine include interferon interferon beta Interferon beta-1b JAMA level 1 Lopinavir Lopinavir-ritonavir Meta-analysis Mild mild to moderate mild to moderate disease moderate disease Mortality network peer-reviewed peer-reviewed study pharmacologic treatment pharmacologic treatments plasma plasma therapy PNAS Prognosis RCT RCTs reduced regimen Remdesivir respiratory Respiratory Support Result ribavirin Ritonavir SARS-CoV-2 searched severe disease significantly study inclusion systematic review Therapies therapy Vaccine [DOI] 10.1016/j.ajem.2020.08.091 PMC 바로가기 [Article Type] Review
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialCOVID-19로 병원에 입원한 환자의 Lopinavir-ritonavir(RECOVERY): 무작위, 통제, 공개, 플랫폼 시험Randomized Controlled Trial Published on 2020-10-242022-08-13 Journal: Lancet (London, England) [Category] 임상, [키워드] 28-day mortality 95% CI active treatment all-cause mortality allocation concealment assigned Azithromycin baseline both groups by mouth composite endpoint death Dexamethasone died discharge discharged eligible finding funding groups hospital Hospital stay Hydroxychloroquine IMPROVE in both groups in vitro activity intention-to-treat basis Invasive mechanical ventilation ISRCTN Lopinavir Lopinavir–ritonavir median Medical Research Council mouth no significant difference observational studies Open-label outcome Participants Patient Platform trial preclinical studies Primary outcome proportion randomisation randomised Randomised trial Randomly rate ratio receive recovery reductions reductions in Registered Result risk risk ratio Ritonavir Standard of care subgroups of patients Support the patient treat Treatment treatment for COVID-19 treatment group Trial usual care web-based simple with COVID-19 [DOI] 10.1016/S0140-6736(20)32013-4 PMC 바로가기 [Article Type] Randomized Controlled Trial
Applying computer simulations in battling with COVID-19, using pre-analyzed molecular and chemical data to face the pandemicReview article Published on 2020-10-172022-10-05 Journal: Informatics in Medicine Unlocked [Category] 신약개발, 유전자 메커니즘, 치료제, [키워드] anti-inflammatory agents antiviral drugs Applying assessment available data clinically Compound Computer simulation Coronavirus disease 2019 COVID-19 creating darunavir docking Drug discovery drugs Effect Efficiency group healthcare service inhibitors Lopinavir Medicines molecular molecular analysis molecular docking Molecular simulation outcome pandemic Patient performed researcher SARS-CoV-2 shown Sirolimus tested the disease Treatment viral entry viral replication with COVID-19 [DOI] 10.1016/j.imu.2020.100458 [Article Type] Review article
Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational studyResearch Published on 2020-10-062022-10-28 Journal: Annals of Intensive Care [Category] COVID-19, [키워드] Acute kidney injury acute respiratory distress age analyzed Antiviral antiviral strategy antiviral therapy Antiviral treatment ARDS ARDS patients benefit BMI Charlson Comorbidity Index chronic renal disease cohort of patient Combination COVID-19 dead dichotomized died Efficacy French group highest Hydroxychloroquine hypertension ICU ICU patient incidence increased risk insight intensive care unit Invasive mechanical ventilation IQR Kidney injury Limited linear mixed model Lopinavir mechanical ventilation median multicentre observé other treatments outcome PaO Patient patients treated primary endpoint receiving Remdesivir renal replacement therapy Result Ritonavir RRT Severe patient Sex Standard of care syndrome treated Treatment Ventilated ventilator-free day VFD [DOI] 10.1186/s13613-020-00751-y PMC 바로가기 [Article Type] Research
QTc prolongation during antiviral therapy in two COVID-19 patients2명의 COVID-19 환자에서 항바이러스 치료 중 QTc 연장Case Reports Published on 2020-10-012022-09-11 Journal: Journal of clinical pharmacy and therapeutics [Category] 치료제, [키워드] Acquired Analysis antiviral drugs antiviral therapy Arrhythmias association baseline contributed coronavirus disease COVID-19 drug Drug interactions Drug-drug interactions during treatment electrocardiogram Electrocardiograms Gender high risk identify individual Long QT syndrome Lopinavir Lopinavir/ritonavir medication metabolism Novel coronavirus novel coronavirus disease Patient patients patients with COVID-19 performed QT prolongation QTc QTc interval QTc interval prolongation QTC prolongation reported Ritonavir secondary to syndrome torsades de pointe torsades de pointes Treatment two COVID-19 patient [DOI] 10.1111/jcpt.13183 PMC 바로가기 [Article Type] Case Reports
Linking hydroxychloroquine to hemolysis in a ‘suspected’ glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection – a critical appraisalComment Published on 2020-10-012023-07-06 Journal: European journal of internal medicine [Category] SARS, [키워드] Antimalarials Chloroquine COVID-19 Glucose-6-phosphate dehydrogenase (G6PD) deficiency haemolysis Hydroxychloroquine Lopinavir [DOI] 10.1016/j.ejim.2020.07.001 PMC 바로가기 [Article Type] Comment
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatmentsReview Published on 2020-10-012023-07-07 Journal: Fundamental & clinical pharmacology [Category] SARS, [키워드] adverse events Hydroxychloroquine Lopinavir Pharmacodynamics pharmacokinetics Therapeutic Drug Monitoring [DOI] 10.1111/fcp.12586 PMC 바로가기 [Article Type] Review
Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain간 이식 환자에서 SARS-CoV-2 감염의 다양한 임상 양상 및 결과: 스페인 마드리드의 단일 센터에서 초기 경험Observational Study Published on 2020-10-012022-09-11 Journal: Transplant infectious disease : an official journa [Category] MERS, SARS, 임상, 진단, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered age baseline broad spectrum consequence coronavirus COVID-19 CT scan diagnosed died discharged home disease severity Drug interactions Dyspnea females Fever Follow-up Hydroxychloroquine immunomodulatory therapy Immunosuppression incidence Infection interferon liver Liver function liver transplant Lopinavir Lopinavir/ritonavir median median age modify one patient onset of symptoms outcome Outpatient Pandemics Patient patients patients with COVID-19 Pneumonia Prognosis question recipients regimen remained respiratory Ritonavir SARS-CoV-2 SARS-COV-2 infection SARS-CoV2 severe acute respiratory syndrome Coronavirus single center single-center Spain still hospitalized Symptoms therapy Tocilizumab transplantation Two patient two patients was used X-ray [DOI] 10.1111/tid.13372 PMC 바로가기 [Article Type] Observational Study